HIF1A and cancer: We would like to argue that patients with HIF-1α overexpressing cancer and a high plasma level of Hsp90α could benefit from treatments such as the monoclonal antibody 1G6-D7, that selectively targets the secreted Hsp90α - a critical downstream effector of HIF-1α.